ClinicalTrials.gg
CompletedNCT03953742Updated Feb 24, 2022

Study of CPI-200 in Patients With Advanced Tumors

A Phase 1 interventional study of CPI-200 in Advanced Solid Tumor, sponsored by Coordination Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-24.

Sponsored by Coordination Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD)

Read the detailed description

Primary Objectives:

  • To determine the safety, tolerability and maximum tolerated dose (MTD) of CPI-200 in patients with advanced tumors

Secondary Objectives:

  • To evaluate the pharmacokinetics (PK) of CPI-200
  • To evaluate clinical response and resolution of symptoms after CPI-200 treatment
  • To characterize adverse events of CPI-200 in patients with advanced cancers

Up to 7 dose levels of CPI-200 will be tested using an accelerated titration method followed by a conventional 3 + 3 dose escalation study design. MTD will be defined as the dose associated with a dose limiting toxicity (DLT) in less than or equal to 33% of patients at the dose level tested. Dose limiting toxicity (DLT) is defined as one of the following events occurring from the intravenous injection of CPI-200 within 21 days:

  • All Grade 4 or greater adverse events as determined by CTCAEv5 criteria, excluding toxicities clearly related to disease progression or inter-current illness
  • Any Grade 3 or greater non-hematologic, non-dermatologic toxicity with the exception of Grade 3 nausea, vomiting or diarrhea if lasting less than 72 hours, alopecia, or Grade 3 fatigue if lasting less than 7 days as determined by CTCAEv5 criteria
  • Grade 3 thrombocytopenia in the presence of bleeding
  • Grade 3 or greater febrile neutropenia
  • Any hematologic or non-hematologic adverse events or abnormal laboratory value(s) related to CPI-200 that result(s) in permanent study discontinuation of study treatment
02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Intravenous infusion
  • Phase 1
  • CPI-200
03

In context

Lead sponsor

Coordination Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Males and females
  • Have a or cytologically confirmed diagnosis of advanced solid tumor
  • Have advanced or disease to standard curative or palliative therapy or to standard therapy
  • Have an performance status of 0-1
  • Have a of at least 12 weeks (in the opinion of the investigator)
  • Have adequate bone marrow reserve, liver and renal function
  • Be reasonably recovered from preceding major surgery and no major surgery within 4 weeks prior to the start of Day 1 treatment
  • Have a negative pregnancy test for females with child bearing age at screening and should not be breast feeding
  • Be willing to abstain from sexual activity or practice physical barrier from study entry to 3 months after the last day of treatment

Exclusion criteria

Exclusion Criteria:

  • Have peripheral sensory neuropathy of Grade 2 or greater at screening
  • Have known to chemotherapeutic agents
  • Have thrombocytopenia with complications including hemorrhage or bleeding > Grade 2 that required medical intervention or any hemolytic condition or coagulation disorders that would make participation unsafe
  • Have unresolved toxicity from previous treatment or previous agents; excluding alopecia
  • Received investigational agents or systemic anticancer agents (other than neurotoxic compounds) within 5 half lives or 28 days, whichever is shorter, prior to Day 1 of treatment
  • Have signs or symptoms of end organ failure, major chronic illnesses other than cancer, or any severe concomitant conditions
  • Have experienced any of the following within the 6-month period prior to screening: unstable angina, myocardial infarction or cerebrovascular accident, , cardiac failure with known less than 40%
  • Have other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study
  • Is pregnant or breast-feeding
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    CPI-200

    Dose Escalation Group: CPI-200 will be administered via intravenous infusion once every 3 weeks for up to 7 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group

    Drug: CPI-200

Interventions

  • DrugCPI-200

    CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    • To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy as assessed by CTCAE

    Time frame: 21 days

Secondary outcomes

  1. Rate of Clinical Benefit

    • To assess clinical benefit by response rate and resolution of symptoms, which will be reported as response rate (%) of participants

    Time frame: through study completion, an average of 4 months

  2. Rate of Adverse Effect

    • To assess adverse effect as either treatment-related or non-treatment-related as defined by CTCAE, which will be reported as % of participants

    Time frame: through study completion, an average of 4 months

  3. Maximum Plasma Concentration (Cmax)

    • To evaluate maximum plasma concentration (Cmax) of CPI-200 in patients tested

    Time frame: 8 Days

  4. Area Under the Curve (AUC)

    • To evaluate area under the curve (AUC) of CPI-200 in patients tested

    Time frame: 8 Days

07

Study locations

1 site
  • South Texas Accelerated Research Therapeutics (START Midwest)
    Grand Rapids, Michigan 49546, United States
08

References and documents

Individual participant data

Plan to share: No — The data will not be shared due to confidentiality agreements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Feb 2022, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 17, 2019
StartActual
Jul 1, 2019
Primary completionActual
Feb 1, 2022
CompletionActual
Feb 15, 2022
Last update
Feb 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03953742
Lead sponsor
Coordination Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 17, 2019
Start date
Jul 1, 2019
Primary completion
Feb 1, 2022
Completion
Feb 15, 2022
Last update
Feb 24, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion